{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:40:40Z","timestamp":1784673640198,"version":"3.55.0"},"reference-count":21,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Frontline therapy for patients with advanced cutaneous melanoma often includes immune checkpoint inhibitors (ICIs). Although these agents have increased response rates, many patients will experience immune-related adverse events (irAEs). The difference in safety profiles of the current combinations available are not well established. Therefore, this study aimed to compare the incidence of severe irAEs of patients receiving ipilimumab-nivolumab versus nivolumab-relatlimab in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective chart review was conducted on all patients who underwent treatment with either combination ICI for advanced cutaneous melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 47 patients who received either one or more doses of either combination ICI were included for analysis. Of these patients, 37 (78.2%) had at least one irAE of any grade. The baseline characteristics among the patients who received nivolumab-relatlimab and those who received ipilimumab-nivolumab were not significantly different. The severity of the 73 irAEs that occurred ranged from grade 1 to grade 3, with 16 (21.9%) irAEs occurring in the nivolumab-relatlimab, 3 (18.8%) of which were grade 3\u20134. Meanwhile, those receiving ipilimumab-nivolumab developed 57 (78.1%) irAEs, with 14 (24.6%) being grade 3\u20134. This study's findings show that nivolumab-relatlimab had a lower incidence of developing severe irAEs in comparison to ipilimumab-nivolumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment with nivolumab-relatlimab could be preferred as a combination ICI given the lower incidence of severe irAEs, delayed onset of irAEs, and lower rate of treatment discontinuation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241303698","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T07:59:32Z","timestamp":1733385572000},"page":"608-616","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Real world comparison of immune-related adverse events with nivolumab-relatlimab versus ipilimumab-nivolumab in patients with advanced cutaneous melanoma"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7764-9118","authenticated-orcid":false,"given":"Brooke","family":"Kielkowski","sequence":"first","affiliation":[{"name":"West Virginia University Hospitals"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Mansour","sequence":"additional","affiliation":[{"name":"West Virginia University Hospitals"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Ebbert","sequence":"additional","affiliation":[{"name":"West Virginia University Hospitals"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsea","family":"Seago","sequence":"additional","affiliation":[{"name":"West Virginia University Hospitals"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijin","family":"Wen","sequence":"additional","affiliation":[{"name":"West Virginia University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Li","sequence":"additional","affiliation":[{"name":"West Virginia University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Barrett","sequence":"additional","affiliation":[{"name":"West Virginia University Hospitals"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01206-X"},{"key":"e_1_3_2_4_2","unstructured":"American Cancer Society. Key statistics for Melanoma Skin Cancer www.cancer.org\/cancer\/types\/melanoma-skin-cancer\/about\/key-statistics.html (2024 accessed 8 August 2023)."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"e_1_3_2_8_2","first-page":"315","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"40","author":"Schneider BJ","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 2022 Jan 20; 40: 315.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.749064"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041106"},{"key":"e_1_3_2_11_2","unstructured":"National Comprehensive Cancer Network. Management of immunotherapy-related toxicities (Version 2.2023) https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf (2023 accessed August 9th 2023)."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970"},{"key":"e_1_3_2_13_2","first-page":"2185","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"379","author":"Wolchok JD","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2018 Nov 29; 379: 2185.","journal-title":"N Engl J Med"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01998"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-024-00599-y"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.908752"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50574-6"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.12.031"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00738-6"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0336-3"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.790"},{"key":"e_1_3_2_22_2","first-page":"2590","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo J","unstructured":"Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol 2017 Aug 1; 35: 2590.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241303698","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241303698","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241303698","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:55:49Z","timestamp":1779274549000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241303698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/10781552241303698"],"URL":"https:\/\/doi.org\/10.1177\/10781552241303698","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]}}}